SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor is trending following news of initiatives aimed at lowering mortgage rates, which the community broadly anticipates will ignite a housing market comeback. Investors are actively discussing a potential short squeeze and rapid price appreciation, believing that increased transaction activity from more accessible mortgage rates will directly benefit Opendoor's business model.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow with Knife ($CAW) is trending with significant community engagement, driven by its multi-chain presence across Solana, Cronos, and Base utilizing Layerzero technology. The community actively promotes its deflationary burn mechanism and organic growth, rallying behind the ambitious mission to become the number one memecoin by surpassing others like Dogecoin. This passionate discussion highlights $CAW's unique characteristics and potential in the evolving crypto landscape.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending sharply upward following a strong earnings report that highlighted massive revenue growth and an ambitious outlook for its AI data center capacity. The community is buzzing with bullish sentiment, fueled by recent analyst upgrades and the CEO's performance-based incentives tied to substantially higher share prices. This enthusiasm reflects APLD's pivotal role in the rapidly expanding AI infrastructure sector as demand for computing power intensifies.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is experiencing significant bullish momentum, largely driven by a recent Bank of America upgrade and widespread community dismissal of a prior bearish analyst report. Investors are actively discussing expectations for imminent news regarding the BlueBird 6 satellite's unfurling and an accelerated deployment schedule, reinforcing conviction in the company's patented direct-to-device cellular broadband technology and its long-term potential in space communications.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is experiencing intense discussion as investors eagerly await its anticipated BLA resubmission to the FDA for deramiocel, following robust Phase 3 HOPE-3 trial results in Duchenne muscular dystrophy. Bulls are confident the compelling efficacy data, particularly for cardiac and limb function, will lead to approval, viewing recent price fluctuations as opportunities. Meanwhile, a polarized community is scrutinizing the submission timeline and significant options activity, with some expressing concerns over potential regulatory responses.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending following its robust presence at CES, showcasing new agentic and conversational AI solutions like Vision AI for vehicles and a partnership with TomTom for multi-agent voice navigation. The community is actively discussing the company's strong growth prospects and expanding partnerships in automotive and robotics, alongside a high short interest that sparks talk of a potential squeeze.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy (MSTR) is a major talking point after MSCI decided against excluding digital-asset firms from its indexes, providing immediate relief from a key overhang. Despite this positive catalyst, community sentiment remains deeply divided, with bulls anticipating a significant reversal or "gamma squeeze" while bears aggressively point to ongoing share dilution and the prevailing "crypto winter" narrative as critical headwinds. Traders are closely watching options expiration and "max pain" levels, fueling intense debate over the stock's direction.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is experiencing significant bearish pressure, notably from a Bank of America downgrade and heightened competition in the weight-loss market with Amazon Pharmacy now offering Novo Nordisk's oral GLP-1 pill. The community is sharply divided, with many expressing deep frustration over consistent daily declines, while others view the current valuation as an attractive buying opportunity, emphasizing the company's fundamental growth, international expansion, and high short interest. Discussions center on whether the stock is a falling knife or poised for a rebound, as investors weigh core business strength against competitive headwinds in the evolving telehealth and GLP-1 sectors.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending sharply higher after Meta Platforms announced a major agreement to develop a 1.2 GW nuclear energy campus for its AI data centers. The community is actively discussing potential short squeezes and anticipated analyst upgrades, though some express skepticism regarding Oklo's current lack of revenue and long-term project timelines. This deal highlights the growing demand for stable, large-scale power solutions for AI infrastructure, positioning advanced nuclear companies in a critical role.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

ARDX is trending as investors digest the potential impact of Fosun Pharma's Wan Ti Le being included on China's National Reimbursement Drug List and analysts anticipate target price raises due to strong IBSRELA sales. The community is weighing potential revenue from China and speculating on milestone payments, while also discussing concerns about patent infringement and generic competition. Some investors express frustration with the stock's price movement despite positive developments, awaiting a CMS resolution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$CNTB @mikeywo But can you trust the data?

$CNTB picked up 16 new watchers on ST. Haha with better data then Dupixent 
This will be next SOC In acute and chronic asthma. Right now  under the radar.

StockTwits for iOS

Connect Biopharma Holdings Ltd - ADR

mikey

StockTwits Web

Prelude Therapeutics Inc

C4 Therapeutics Inc

BioAtla Inc

Gain Therapeutics Inc

Werewolf Therapeutics Inc

Monte Rosa Therapeutics Inc

Immuneering Corp

MAIA Biotechnology Inc

LabPsycho

Well, the FDA  trusted it enough to  tell  management that they could  move to Phase 3 (which they  have elected  to defer  until  the  completion of the two ongoing Phase  2  Seabreeze  studies.)  So, what’s your  point?